BRCA 1/2 Panel
Addressing the Global Burden of Breast Cancers
Breast and ovarian cancers continue to pose serious health challenges worldwide, impacting millions of women each year. As per World Health Organization data (2024), approximately 2.5 million new breast cancer cases and over 700,000 related deaths occur annually, while ovarian cancer accounts for an additional 310,000 new cases globally.
In India, the ICMR–NCRP (2025) reports nearly 232,832 breast cancer and 49,644 ovarian cancer cases each year. Breast cancer is the most frequently diagnosed cancer among Indian women, emphasizing the urgent need for enhanced awareness, early screening, and timely medical intervention.
Around 20–30% of hereditary cancer cases in India are associated with mutations in the BRCA1 and BRCA2 genes. Identifying these mutations early supports individualized risk evaluation, preventive care, and targeted therapeutic decisions—ultimately improving patient prognosis and survival outcomes.
Introducing the UNCODED BRCA1/2 Panel
The UNCODED BRCA1/2 Panel is a powerful NGS-based assay designed to deliver precise and actionable insights for hereditary cancer diagnostics and research. Utilizing advanced bioinformatics, it ensures accurate, consistent, and reproducible variant interpretation while addressing the limitations of traditional methods.
Why Choose UNCODED BRCA1/2 Panel
This high-performance NGS panel is tailored for comprehensive detection of clinically significant BRCA1 and BRCA2 mutations. Its optimized design and analytical workflow provide:
Actionable Insights: Supports clinicians in assessing risk, planning preventive strategies, and guiding personalized therapy.
Accurate Variant Detection: Confidently identifies pathogenic and clinically relevant BRCA mutations.
Scalable Workflow: Efficiently handles multiple samples, suitable for both research studies and clinical applications.
Clinical Utility: Facilitates genetic counselling and informed decision-making for patients and their families.
Next-Generation Sequencing (NGS) provides a high-throughput, comprehensive approach for analyzing genetic material. It allows simultaneous detection of multiple genetic variants, accelerates research, and delivers precise insights for diverse genomic applications.
Unlocking the Power of NGS in Genetic Analysis
Applications
The UNCODED BRCA1/2 Panel equips clinicians and researchers with dependable detection of BRCA1 and BRCA2 variants, establishing it as a trusted solution for hereditary cancer risk assessment and precision oncology worldwide.
| Cat. No. | Kit Name | Rxns |
| 13911 | BRCA1/2 Panel | 8 |
| 13913 | BRCA1/2 Panel | 24 |
| 13915 | BRCA1/2 Panel | 96 |
-20 °C to 4 °C
Frequently Asked Questions
Curious about workflow, accuracy, or compatibility? Find all your answers here
What are the challenges of 16S V3-V4?
How does16S V3-V4 improve compliance?
Lorem ipsum dolor sit amet consectetur. Dolor aenean lorem integer nunc at nascetur enim. At porta eu imperdiet porta condimentum vitae in lacus. Amet placerat senectus justo integer nulla lobortis bibendum sed quam. Morbi consequat iaculis et est elementum in.
What is 16S V3-V4?
Lorem ipsum dolor sit amet consectetur. Dolor aenean lorem integer nunc at nascetur enim. At porta eu imperdiet porta condimentum vitae in lacus. Amet placerat senectus justo integer nulla lobortis bibendum sed quam. Morbi consequat iaculis et est elementum in.
How does16S V3-V4 improve compliance?
Lorem ipsum dolor sit amet consectetur. Dolor aenean lorem integer nunc at nascetur enim. At porta eu imperdiet porta condimentum vitae in lacus. Amet placerat senectus justo integer nulla lobortis bibendum sed quam. Morbi consequat iaculis et est elementum in.
Learn more about : BRCA 1/2 Panel
